BMS-754807 Clinical Trials

Size	Price	Qty
5mg	USD 180
50mg	USD 770

Clinical Trials

Multiple Phase 1 and Phase 1/2 clinical trials sponsored by Bristol-Myers Squibb have evaluated BMS-754807 as monotherapy and in combination with targeted biological agents to determine its safety, pharmacokinetics, and therapeutic efficacy. These completed and terminated studies investigated the compound across several populations, including healthy volunteers and patients with advanced or metastatic solid tumors, breast cancer, colorectal cancer, and head and neck cancer.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01225172	TERMINATED	Breast Cancer	Bristol-Myers Squibb	2010-12-31	PHASE2
NCT00569036	COMPLETED	Neoplasms; Solid Tumors; Metastases	Bristol-Myers Squibb	2008-04	PHASE1
NCT00908024	TERMINATED	Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis	Bristol-Myers Squibb	2009-10	PHASE1; PHASE2
NCT00793897	COMPLETED	Advanced Solid Tumors; Metastatic Solid Tumors	Bristol-Myers Squibb	2009-04	PHASE1
NCT01525823	COMPLETED	Healthy Volunteers	Bristol-Myers Squibb	2012-02	PHASE1
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	2012-02	Phase 1
NCT00788333	COMPLETED	Breast Cancer	Bristol-Myers Squibb	2009-07	PHASE1; PHASE2
NCT00898716	COMPLETED	Neoplasms	Bristol-Myers Squibb	2009-09	PHASE1
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	2009-10	Phase 1\|Phase 2
NCT00898716	Completed	Neoplasms	Bristol-Myers Squibb	2009-09	Phase 1
NCT00788333	Completed	Breast Cancer	Bristol-Myers Squibb	2009-07	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2020-08-11)

Check the BMS-754807 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

BMS-754807 acts as a potent, reversible inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR), blocking receptor autophosphorylation and suppressing downstream signaling through Akt and MAPK pathways. Consequently, this molecular blockade inhibits cellular proliferation and induces tumor regression, providing the rationale for its clinical investigation in subjects with advanced solid tumors, breast cancer, and colorectal cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).